FASCINATION ABOUT 2'

Contraindicated (one)bortezomib will increase the degree or result of mavacamten by affecting hepatic enzyme CYP2C19 metabolism. Contraindicated. Robust or moderate CYP2C19 inhibitors might improve mavacamten systemic exposure, causing heart failure resulting from systolic dysfunction.elvitegravir/cobicistat/emtricitabine/tenofovir DF raises levels